JAMP-ATORVASTATIN 40 MG
ATORVASTATIN (ATORVASTATIN CALCIUM) : 40 MG · DIN 02391074 · JAMP PHARMA CORPORATION
Health Canada status: DORMANT
What is JAMP-ATORVASTATIN?
JAMP-ATORVASTATIN 40 MG contains ATORVASTATIN (ATORVASTATIN CALCIUM) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02391074, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-ATORVASTATIN used for?
Adjunct to diet for reduction of elevated lipids in hyperlipidemia and dyslipidemia; prevention of cardiovascular disease (myocardial infarction and stroke) in high-risk patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02391074 |
|---|---|
| Brand name | JAMP-ATORVASTATIN |
| Generic / active ingredient | ATORVASTATIN (ATORVASTATIN CALCIUM) : 40 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 40 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA05 ATORVASTATIN |
| AHFS class | 24:06.08 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 31-Jul-2025 |
| Original market date | 2012-09-10 00:00:00 |
How is it administered?
10-80 mg once daily. Adjustments at 2-4 week intervals. Can be taken any time of day, with or without food. Starting dose usually 10 or 20 mg; 10 mg in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to full monograph section 11).
How is it supplied?
Bottles of 90 and 500 tablets.
Contraindications
Hypersensitivity to any ingredient; active liver disease or unexplained persistent elevations of serum transaminases; pregnancy and breastfeeding; concomitant use of hepatitis C antivirals or cyclosporine.
Warnings and precautions
Risk of myopathy and rhabdomyolysis; liver function tests required before initiation; risk of hemorrhagic stroke in patients with recent stroke/TIA; potential for increased HbA1c/glucose levels.
Is ATORVASTATIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AA05 ATORVASTATIN. 87 of 216 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ATORVASTATIN CALCIUM | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457741 |
| ACH-ATORVASTATIN CALCIUM | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457768 |
| ACH-ATORVASTATIN CALCIUM | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457776 |
| ACH-ATORVASTATIN CALCIUM | 80 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02457784 |
| APO-ATORVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02295261 |
| APO-ATORVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02295288 |
| APO-ATORVASTATIN | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02295296 |
| APO-ATORVASTATIN | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02295318 |
| ATORVASTATIN | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02346486 |
| ATORVASTATIN | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02348705 |
Who else supplies ATORVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATORVASTATIN appears in 2136 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.